Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
The chart shows the growth of an initial investment of $10,000 in Prothena Corporation plc Ordinary Shares, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Prothena Corporation plc Ordinary Shares (PRTA) has returned 3.14% so far this year and -4.92% over the past 12 months. Looking at the last ten years, PRTA has achieved an annualized return of -13.74%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Prothena Corporation plc Ordinary Shares (PRTA) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.85% | -1.37% | 6.93% | 0.20% | ||||||||
| 2025 | 1.57% | 14.57% | -21.92% | -25.02% | -50.16% | 33.11% | 13.37% | 20.59% | 19.46% | 9.81% | -0.05% | -13.02% |
| 2024 | -20.76% | -3.87% | -11.09% | -18.38% | 1.07% | -2.82% | 13.28% | -4.67% | -24.74% | 1.61% | -4.82% | -15.96% |
| 2023 | -6.94% | -1.31% | -13.25% | 9.03% | 26.32% | 2.77% | 2.14% | -22.69% | -9.73% | -23.87% | -9.58% | 11.95% |
| 2022 | -31.53% | 1.20% | 7.02% | -20.59% | -6.14% | -0.91% | 13.90% | -9.67% | 122.66% | 0.89% | -0.13% | -3.62% |
| 2021 | -8.04% | 95.79% | 10.37% | 6.93% | 7.88% | 76.48% | -2.13% | 33.20% | 6.31% | -21.42% | -9.05% | -2.54% |
| 2020 | -23.79% | -13.33% | -0.56% | 10.00% | -2.65% | -1.88% | 16.91% | 5.19% | -22.74% | 8.67% | 3.38% | 5.81% |
| 2019 | 15.65% | 14.04% | -10.28% | -13.48% | -10.47% | 13.17% | -12.52% | -10.15% | -5.77% | 16.07% | 39.65% | 23.48% |
| 2018 | 9.62% | -19.07% | 9.03% | -67.42% | 12.23% | 6.89% | 2.77% | 2.49% | -13.66% | -5.70% | -3.61% | -16.46% |
| 2017 | -2.22% | 18.97% | -6.28% | -3.34% | -5.94% | 5.72% | 14.31% | -1.48% | 5.44% | -10.38% | -20.84% | -19.24% |
| 2016 | 5.78% | 11.92% | -28.15% | 56.17% | -8.73% | 19.84% | -20.45% | 22.25% | -17.38% |
The charts below present risk-adjusted performance metrics for Prothena Corporation plc Ordinary Shares (PRTA) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of PRTA compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Prothena Corporation plc Ordinary Shares volatility is 2.80%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 326.80M | 547.11M | 696.38M | 758.04M | 609.37M | 332.98M | 419.27M | 498.80M | 496.33M | 459.98M | 385.24M | 304.12M | 182.41M |
| Equity Attributable To Parent (USD) | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M | 323.00M | 407.19M | 365.40M | 360.67M | 289.89M | 173.27M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M | 323.00M | 407.19M | 365.40M | 360.67M | 289.89M | 173.27M |
| Noncurrent Liabilities (USD) | 5.49M | 11.68M | 78.13M | 85.85M | 109.87M | 123.12M | 128.63M | 160.87M | 51.77M | 53.50M | 2.35M | 2.19M | 1.73M |
| Other Current Liabilities (USD) | 23.62M | 26.26M | 18.26M | 29.82M | 21.12M | 15.80M | 11.65M | 8.95M | 16.40M | 21.38M | 13.92M | 4.18M | 2.82M |
| Wages (USD) | 11.35M | 14.47M | 13.25M | 11.06M | 8.64M | 5.93M | 4.82M | 4.51M | 7.34M | 6.63M | 3.77M | 3.14M | 2.80M |
| Accounts Payable (USD) | 5.88M | 7.77M | 25.39M | 9.27M | 3.69M | 4.12M | 1.24M | 1.47M | 13.63M | 13.07M | 4.52M | 4.72M | 1.79M |
| Current Liabilities (USD) | 40.84M | 48.50M | 56.89M | 50.15M | 33.45M | 25.85M | 17.71M | 14.93M | 37.37M | 41.08M | 22.22M | 12.04M | 7.41M |
| Liabilities (USD) | 46.33M | 60.18M | 135.02M | 135.99M | 143.32M | 148.97M | 146.35M | 175.80M | 89.14M | 94.57M | 24.57M | 14.23M | 9.14M |
| Other Non-current Assets (USD) | 9.47M | 58.62M | 53.26M | 37.21M | 22.55M | 31.14M | 37.02M | 14.57M | 15.01M | 12.16M | 3.97M | 1.72M | 816.00K |
| Fixed Assets (USD) | 2.14M | 3.08M | 3.84M | 1.73M | 2.01M | 2.55M | 3.87M | 52.84M | 54.99M | 56.45M | 3.86M | 3.12M | 3.37M |
| Noncurrent Assets (USD) | 11.61M | 61.70M | 57.10M | 38.94M | 24.56M | 33.69M | 40.89M | 67.41M | 70.00M | 68.61M | 7.83M | 4.84M | 4.19M |
| Current Assets (USD) | 315.19M | 485.41M | 639.28M | 719.10M | 584.81M | 299.28M | 378.38M | 431.39M | 426.33M | 391.36M | 377.40M | 299.28M | 178.22M |
| Assets (USD) | 326.80M | 547.11M | 696.38M | 758.04M | 609.37M | 332.98M | 419.27M | 498.80M | 496.33M | 459.98M | 385.24M | 304.12M | 182.41M |
Novo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.
The FDA now requires an additional MRI scan before the third Leqembi infusion to detect early signs of brain swelling (ARIA-E), a rare but potentially fatal side effect of the Alzheimer's treatment.
Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.
Prothena's Parkinson's drug prasinezumab, partnered with Roche, missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses.
The rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.